Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 Chagas disease 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
2 Chagas disease 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
3 Chagas disease 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
4 Chagas disease 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
5 Epstein-Barr virus infection 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
6 Epstein-Barr virus infection 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
7 Epstein-Barr virus infection 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
8 Epstein-Barr virus infection 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
9 Hematopoietic cell lineage 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
10 Hematopoietic cell lineage 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
11 Hematopoietic cell lineage 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
12 Hematopoietic cell lineage 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
13 Human immunodeficiency virus 1 infection 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
14 Human immunodeficiency virus 1 infection 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
15 Human immunodeficiency virus 1 infection 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
16 Human immunodeficiency virus 1 infection 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
17 Human T-cell leukemia virus 1 infection 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
18 Human T-cell leukemia virus 1 infection 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
19 Human T-cell leukemia virus 1 infection 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
20 Human T-cell leukemia virus 1 infection 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
21 Measles 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
22 Measles 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
23 Measles 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
24 Measles 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
25 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
26 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
27 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
28 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
29 Primary immunodeficiency 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
30 Primary immunodeficiency 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
31 Primary immunodeficiency 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
32 Primary immunodeficiency 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
33 T cell receptor signaling pathway 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
34 T cell receptor signaling pathway 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
35 T cell receptor signaling pathway 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
36 T cell receptor signaling pathway 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
37 Th1 and Th2 cell differentiation 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
38 Th1 and Th2 cell differentiation 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
39 Th1 and Th2 cell differentiation 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
40 Th1 and Th2 cell differentiation 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
41 Th17 cell differentiation 💬
 [1] CD3D 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
42 Th17 cell differentiation 💬
 [1] CD3D 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
43 Th17 cell differentiation 💬
 [1] CD3D 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
44 Th17 cell differentiation 💬
 [1] CD3D 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬

Back to top